Capstone Therapeutics (NASDAQ:CAPS) Shares Down 3.1% – Here’s What Happened
by Michael Walen · The Markets DailyCapstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) traded down 3.1% during trading on Friday . The company traded as low as $0.25 and last traded at $0.2564. Approximately 124,383 shares changed hands during trading, a decline of 39% from the average daily volume of 202,915 shares. The stock had previously closed at $0.2647.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Get Our Latest Stock Analysis on Capstone Therapeutics
Capstone Therapeutics Price Performance
The firm has a market cap of $3.90 million, a P/E ratio of -0.08 and a beta of -1.51. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.95 and a quick ratio of 0.29. The stock’s 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $0.51.
Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The firm had revenue of $12.64 million during the quarter, compared to analysts’ expectations of $10.80 million. Capstone Therapeutics had a negative return on equity of 114.15% and a negative net margin of 41.26%.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent reporting period. 2.55% of the stock is currently owned by institutional investors and hedge funds.
About Capstone Therapeutics
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.